Liqin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Liqin Wang has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- René Bernards
Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
38 shared publications - Rodrigo Leite de Oliveira
Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
27 shared publications - Alaa Embaby
Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 1
21 shared publications - Alwin D. R. Huitema
Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
21 shared publications - Bastiaan Nuijen
Netherlands Cancer Institute 5 Division of Pharmacy and Pharmacology Amsterdam, the Netherlands
21 shared publications - Charlaine van Steenis
Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 11
21 shared publications
Latest Publications
- 20 August 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (9) , 1750-1751
Turning CDK4/6 inhibitors against the dark side of senescence
- 20 August 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (9) , 1750-1751
Turning CDK4/6 inhibitors against the dark side of senescence
- Open Access
- 27 May 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Correction: The KLF16/MYC feedback loop is a therapeutic target in bladder cancer
- 27 May 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Open AccessCorrection: The KLF16/MYC feedback loop is a therapeutic target in bladder cancer
- 17 April 2026
- Published by Elsevier in Trends in Immunology
- Vol. 47 (8) , 683-699
Exploiting immunogenic cell death to promote antitumor immunity
- 17 April 2026
- Published by Elsevier in Trends in Immunology
- Vol. 47 (8) , 683-699
Exploiting immunogenic cell death to promote antitumor immunity
- 8 October 2025
- Published by Springer Nature in Nature Protocols
- Vol. 21 (5) , 1896-1926
Inducible CRISPR–Cas9 screening platform to interrogate non-proliferative cellular states
CRISPR screens have revolutionized the study of diverse biological processes, particularly in cancer research. Both pooled and arrayed CRISPR screens have facilitated the identification of essential genes for cell survival and proliferation, drivers of drug resistance and synthetic lethal interactions. However, applying loss-of-function CRISPR screening to non-proliferative states remains challenging, largely because of slower editing and the poor sensitivity of identifying guide RNAs that ‘drop out’ in a population of non-dividing cells. Here, we present a detailed protocol to accomplish this, using an inducible Cas9 system that offers precise temporal control over Cas9 expression. This inducible system allows gene editing to occur only after the non-proliferative state is fully established. We describe the complete procedure for generating an inducible Cas9-expressing model and for measuring editing efficiency by using flow cytometry. In addition, we discuss how to optimize key parameters for performing successful CRISPR screens in various non-proliferative states. We describe a detailed workflow for performing a screen in senescent cells to identify senolytic targets. This protocol is accessible to researchers with experience in molecular biology techniques and can be completed in 8–12 weeks, from the generation of an inducible Cas9 cell line clone to the analysis of a CRISPR screen for hit identification. These techniques can be applied by researchers across different fields, including stem cell differentiation, immune cell development, aging and cancer research.
- 8 October 2025
- Published by Springer Nature in Nature Protocols
- Vol. 21 (5) , 1896-1926
Inducible CRISPR–Cas9 screening platform to interrogate non-proliferative cellular states
CRISPR screens have revolutionized the study of diverse biological processes, particularly in cancer research. Both pooled and arrayed CRISPR screens have facilitated the identification of essential genes for cell survival and proliferation, drivers of drug resistance and synthetic lethal interactions. However, applying loss-of-function CRISPR screening to non-proliferative states remains challenging, largely because of slower editing and the poor sensitivity of identifying guide RNAs that ‘drop out’ in a population of non-dividing cells. Here, we present a detailed protocol to accomplish this, using an inducible Cas9 system that offers precise temporal control over Cas9 expression. This inducible system allows gene editing to occur only after the non-proliferative state is fully established. We describe the complete procedure for generating an inducible Cas9-expressing model and for measuring editing efficiency by using flow cytometry. In addition, we discuss how to optimize key parameters for performing successful CRISPR screens in various non-proliferative states. We describe a detailed workflow for performing a screen in senescent cells to identify senolytic targets. This protocol is accessible to researchers with experience in molecular biology techniques and can be completed in 8–12 weeks, from the generation of an inducible Cas9 cell line clone to the analysis of a CRISPR screen for hit identification. These techniques can be applied by researchers across different fields, including stem cell differentiation, immune cell development, aging and cancer research.
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Immunotherapy has made remarkable strides in the treatment of solid tumors, but its efficacy as a single agent in immunologically cold tumors remains limited. Therefore, it is necessary to explore novel drug combinations to further optimize immunotherapy. Herein, we demonstrated that the histone deacetylase inhibitor (HDACi) chidamide enhanced chromatin accessibility at the promoters of genes that encode effector molecules in CD8+ T cells, thereby augmenting their antitumor capabilities. However, HDACi also induced the expression of VEGFA in protumorigenic macrophages, which led to vascular abnormalization and hindered immune cell infiltration, compromising its potential synergistic effect with immunotherapy. Accordingly, combining antiangiogenic therapy counteracted the angiogenic effects of HDACi, collaboratively unleashing the infiltration and functionality of cytotoxic CD8+ T cells. These findings were confirmed by single-cell RNA sequencing data from our patient samples. Thus, through mechanistic research, we propose a new therapeutic approach by the combination of HDACi, antiangiogenic therapy, and immunotherapy, highlighting its potential application across diverse solid tumors.Significance:The challenges of tumor therapy primarily lie in developing novel intervention strategies to shift the tumor microenvironment toward an antitumor phenotype. Herein, we discovered that the combination of HDACi and antiangiogenic therapy promoted the functionality and infiltration of CD8+ T cells, ultimately remodeling the tumor microenvironment and boosting immunotherapy efficacy.
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Immunotherapy has made remarkable strides in the treatment of solid tumors, but its efficacy as a single agent in immunologically cold tumors remains limited. Therefore, it is necessary to explore novel drug combinations to further optimize immunotherapy. Herein, we demonstrated that the histone deacetylase inhibitor (HDACi) chidamide enhanced chromatin accessibility at the promoters of genes that encode effector molecules in CD8+ T cells, thereby augmenting their antitumor capabilities. However, HDACi also induced the expression of VEGFA in protumorigenic macrophages, which led to vascular abnormalization and hindered immune cell infiltration, compromising its potential synergistic effect with immunotherapy. Accordingly, combining antiangiogenic therapy counteracted the angiogenic effects of HDACi, collaboratively unleashing the infiltration and functionality of cytotoxic CD8+ T cells. These findings were confirmed by single-cell RNA sequencing data from our patient samples. Thus, through mechanistic research, we propose a new therapeutic approach by the combination of HDACi, antiangiogenic therapy, and immunotherapy, highlighting its potential application across diverse solid tumors.Significance:The challenges of tumor therapy primarily lie in developing novel intervention strategies to shift the tumor microenvironment toward an antitumor phenotype. Herein, we discovered that the combination of HDACi and antiangiogenic therapy promoted the functionality and infiltration of CD8+ T cells, ultimately remodeling the tumor microenvironment and boosting immunotherapy efficacy.
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Video S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The video of 3D images in tumor tissues treated with CP regimen
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The video of 3D images in tumor tissues treated with CP regimen
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
HDAC inhibitor hinders the infiltration of CD8+ T cells
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
HDAC inhibitor hinders the infiltration of CD8+ T cells
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The gating strategy of main cell types and T cells through flow cytometry in this article
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The gating strategy of main cell types and T cells through flow cytometry in this article
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
HDAC inhibitor promotes the expression of VEGFa in macrophage
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
HDAC inhibitor promotes the expression of VEGFa in macrophage